A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

NCT01435863 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG: SP-02L (darinaparsin for injection)
DRUG: SP-02L (darinaparsin for injection)
DRUG: SP-02L (darinaparsin for injection)

Sponsor

Solasia Pharma K.K.